Compass Therapeutics Reports 2024 Second Quarter Financial Results and Provides Corporate Update
12 août 2024 08h00 HE
|
Compass Therapeutics
Compass Therapeutics announces 2nd quarter results and provides clinical results update
Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin’s Lymphoma
12 août 2024 07h00 HE
|
Marker Therapeutics
HOUSTON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for...
Tevogen Bio’s Founding CEO, Ryan Saadi, Expresses Conviction in Company’s Growth Strategy and Reaffirms Newly Effective Form S-1 Does Not Relate to Previously Undisclosed New Issuance of Dilutive Securities
09 août 2024 11h00 HE
|
Tevogen Bio Inc
Tevogen Bio reaffirms that the registration statement does not relate to any previously undisclosed new issuances of dilutive securities.
Renown Health pioneers HistoSonics Edison system delivering histotripsy for non-invasive liver tumor treatment
08 août 2024 16h18 HE
|
Renown Health
Reno, NEV., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Renown Health announced today that the first patients have received targeted liver tumor treatments through the Edison® System histotripsy technology,...
Oncocyte Announces Successful GraftAssure™ Beta Launch and Q2 2024 Results
08 août 2024 16h05 HE
|
OncoCyte Corporation
Oncocyte Announces Successful GraftAssureTM Beta Launch and Q2 2024 Results
CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates
08 août 2024 08h23 HE
|
CG Oncology Inc.
CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates
Revolution Medicines Reports Second Quarter 2024 Financial Results and Update on Corporate Progress
07 août 2024 16h05 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
Kymera Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update
07 août 2024 07h00 HE
|
Kymera Therapeutics, Inc.
Sanofi plans to expand KT-474/SAR444656 (IRAK4) Phase 2 clinical trials in HS and AD to accelerate overall development timelines following interim analysis of safety and efficacy data STAT6 degrader...
Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates
06 août 2024 16h05 HE
|
Immuneering Corporation
Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates
Oncocyte Announces August Investor Conferences Participation
05 août 2024 16h05 HE
|
OncoCyte Corporation
Oncocyte Announces August Investor Conferences Participation